Beauvericin (CAS 26048-05-5) induces apoptosis in A549 cancer cells.1 Disrupts mitochondrial volume regulation.2 Antifungal activity acting via inhibition of both multidrug efflux and TORC1 kinase.3 Crosses the blood-brain barrier in mice.4 Inhibits HIV-1 integrase.5
Toxic depsipeptide with antibiotic and insecticidal effects.Beauvericin is a toxic depsipeptide with antibiotic and insecticidal effects.
Beauvericin is a cyclic depsipeptide isolated from several fungal genera, notably Beauveria and Fusarium, first reported in 1969. Beauvericin exhibits broad antifungal, antibacterial, antiprotozoan and insecticidal activities. At the molecular level, beauvericin exhibits ionophoric properties, and inhibits acyl-CoA:cholesterol acyltransferase activity. Beauvericin induces apoptosis by elevating intracellular calcium levels.
ChEBI: A trimeric cyclodepsipeptide composed from alternating methylphenylalanyl and hydroxyvaleryl residues.
1) Lu et al. (2016), Beauvericin-induced cell apoptosis through the mitogen-activated protein kinase pathway in human nonsmall cell lung cancer A549 cells.; J. Toxicol. Sci., 41 429
2) Tonshin et al. (2010), The Fusarium mycotoxins enniatins and beauvericin cause mitochondrial dysfunction by affecting the mitochondrial volume regulation, oxidative phosphorylation and ion homeostasis.; Toxicology, 276 49
3) Shekhar-Guturja et al. (2016), Dual action antifungal small molecule modulates multidrug efflux and TOR signaling; Nat. Chem. Biol., 12 867
4) Taevernier et al. (2016), Blood-brain barrier transport kinetics of the cyclic depsipeptide mycotoxins beauvericin and enniatins; Toxicol. Lett., 258 175
5) Shin et al. (2009), Beauvericin and enniatins H,I and MK1688 are new potent inhibitors of human immunodeficiency virus type-1 integrase; J. Antibiot. (Tokyo), 62 687
